Potent and selective CB1 receptor antagonist (Ki values are 1 and > 10000 nM at CB1 and CB2 receptors respectively). Inhibits food intake in vivo following oral administration.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 452.28. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.21 mL||11.06 mL||22.11 mL|
|5 mM||0.44 mL||2.21 mL||4.42 mL|
|10 mM||0.22 mL||1.11 mL||2.21 mL|
|50 mM||0.04 mL||0.22 mL||0.44 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Dow et al (2009) iscovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazole[3,4-f][1,4]oxazepin-8-(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of J.Med.Chem. 52 2652 PMID: 19351113
If you know of a relevant reference for PF 514273, please let us know.
View Related Products by Product Action
Keywords: Potent and selective CB1 agonists cannabinoids Receptors PF514273 cb1r CB1 Receptors
1 Citation for PF 514273
Citations are publications that use Tocris products. Selected citations for PF 514273 include:
Rozenfeld et al (2011) AT1R-CB1R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J 30 2350 PMID: 21540834
Do you know of a great paper that uses PF 514273 from Tocris? If so please let us know.
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.